发明授权
US08632967B2 Cancer marker, method for evaluation of cancer by using the cancer marker, and evaluation reagent
有权
癌症标记，通过使用癌症标记物评估癌症的方法和评估试剂
- 专利标题： Cancer marker, method for evaluation of cancer by using the cancer marker, and evaluation reagent
- 专利标题（中）： 癌症标记，通过使用癌症标记物评估癌症的方法和评估试剂
-
申请号： US13472190申请日： 2012-05-15
-
公开(公告)号： US08632967B2公开(公告)日： 2014-01-21
- 发明人: Masahiko Kuroda , Masami Tanaka , Kosuke Oikawa , Takayuki Mizutani , Masakatsu Takanashi , Seiko Iizuka , Yoshinori Kosugi , Kazuma Ohyashiki , Akihiko Tsuchida
- 申请人： Masahiko Kuroda , Masami Tanaka , Kosuke Oikawa , Takayuki Mizutani , Masakatsu Takanashi , Seiko Iizuka , Yoshinori Kosugi , Kazuma Ohyashiki , Akihiko Tsuchida
- 申请人地址： JP Tokyo JP Tokyo
- 专利权人： NEC Corporation,Tokyo Medical University
- 当前专利权人： NEC Corporation,Tokyo Medical University
- 当前专利权人地址： JP Tokyo JP Tokyo
- 代理机构： Sughrue Mion, PLLC
- 优先权： JP2008-119280 20080430
- 主分类号： C12Q1/68
- IPC分类号： C12Q1/68
摘要：
The present invention provides a novel cancer marker for evaluating the onset, the preclinical stage, the clinical stage, or the prognosis of a cancer in a subject, and an evaluation method using the same. A cancer marker containing at least one miRNA selected from hsa-miR-92 and hsa-miR-494 is used as a marker for cancers excluding breast cancer. A method for evaluating the possibility of cancers excluding breast cancer includes the step of detecting the expression level of a cancer marker in a biological sample collected from a subject. In this method, the cancer marker contains at least one miRNA selected from hsa-miR-92 and hsa-miR-494.
公开/授权文献
信息查询
